Stopping GLP-1: What to Discuss With Your Doctor First

At some point, nearly every patient on a GLP-1 medication asks: "Can I stop?" Maybe it's the cost. Maybe you've reached your goal weight. Maybe the side effects have become more trouble than they're worth. Whatever the reason, the decision to stop should be informed — not impulsive — because the data on what happens after discontinuation is clear, and it's not what most patients expect.

What the Weight Regain Data Actually Shows

The weight regain pattern after stopping GLP-1s is well-documented across multiple clinical trials:

• SURMOUNT-4 (tirzepatide): Patients who switched from tirzepatide to placebo regained approximately two-thirds of lost weight over the following year. Cardiometabolic improvements also reversed.
• STEP 1 extension data (semaglutide): After discontinuation, patients regained most of the weight they had lost, with the majority returning close to their original weight within 12–18 months.
• Real-world data (Epic Research, 2025): Analysis of large patient populations found that while most patients regained weight after stopping, many did sustain some net loss — averaging 5–10% below their starting weight at the two-year mark.

This doesn't mean the medication "didn't work." It means obesity is a chronic metabolic condition — similar to hypertension or diabetes — where the underlying biology reasserts itself when treatment stops. Your body's weight set point, hormone levels, and metabolic rate didn't permanently reset during treatment. They were managed by the medication.

When Stopping Makes Clinical Sense

Despite the regain data, there are legitimate clinical scenarios where stopping is the right decision:

• Intolerable side effects that persist despite dose reduction and management strategies
• Pregnancy planning — GLP-1s must be stopped at least two months before attempting conception
• Concerning lab results — persistent kidney function decline, pancreatitis markers, or other contraindications that develop during treatment
• Financial unsustainability — if the cost is causing financial harm, stopping may be necessary (with a plan for alternatives)
• Surgical preparation — some surgeons require patients to stop GLP-1s before elective surgery due to concerns about delayed gastric emptying and aspiration risk during anesthesia

The Maintenance Dose Option

Before stopping entirely, discuss a maintenance dose with your provider. The concept is straightforward: instead of staying at the maximum therapeutic dose indefinitely, you step down to a lower dose that maintains your weight loss with fewer side effects and lower cost.

For semaglutide, some providers use 1.0 mg or 1.7 mg as maintenance doses (versus the 2.4 mg treatment dose). For tirzepatide, 5.0 mg or 7.5 mg maintenance is being explored clinically. The evidence for specific maintenance protocols is still emerging, but the principle — minimum effective dose for weight maintenance — is well-established in obesity medicine.

If You Do Decide to Stop

Here's what to discuss with your provider before your last injection:

1. Tapering vs. Cold Turkey

There's no established tapering protocol for GLP-1s — they don't cause physical dependence. However, some providers recommend stepping down one dose level for 4 weeks before stopping, which may give your body a more gradual adjustment. The main benefit is psychological: it gives you time to calibrate your appetite awareness as the medication's effects diminish.

2. Appetite Return Timeline

Most patients notice their appetite returning within 1–3 weeks of their last injection. The "food noise" comes back. Cravings return. Portion sizes creep up. This isn't weakness — it's your hypothalamus recalibrating. Knowing it's coming helps you prepare rather than panic.

3. Lifestyle Infrastructure

The patients who retain the most weight loss after stopping are those who built sustainable habits during treatment: regular exercise (especially resistance training), high-protein eating patterns, consistent meal timing, and sleep hygiene. Treatment is an opportunity to establish these habits while your appetite is manageable. If you haven't built them, stopping the medication will be significantly harder.

4. Monitoring After Discontinuation

Ask your provider to schedule follow-up labs 3 months after stopping. Blood sugar, lipids, and metabolic markers may shift as weight regain occurs. Catching changes early allows for intervention — whether that's restarting the medication, switching to an alternative, or adjusting other treatments.

The Bottom Line

Stopping a GLP-1 is a medical decision, not a finish line. The data strongly suggests that most patients will regain a significant portion of lost weight without medication support. That's not a character flaw — it's how chronic metabolic conditions work. Have the conversation with your provider before you stop, explore maintenance dosing, build the lifestyle habits that give you the best shot at sustaining results, and have a plan for monitoring afterward.